Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via aerolizer(TM)

European Journal of Clinical Pharmacology

Volumn 55, Issue 2, 1999, Pages 131-138

  Lecaillon, J B ^a   Kaiser, G ^b   Palmisano, M ^c   Morgan, J ^d   Della Cioppa, G ^e  

^a NOVARTIS PHARMA K K   (Japan)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d Cardiovasc Dis Prevention Center   (United States)

^e NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Extremely fast absorption; Slow elimination; Tolerability

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL FUMARATE; POTASSIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG URINE LEVEL; ENANTIOMER; FEMALE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; MALE; NERVOUSNESS; NORMAL HUMAN; POTASSIUM BLOOD LEVEL; POWDER INHALER; PRIORITY JOURNAL; QT INTERVAL; TACHYCARDIA;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AREA UNDER CURVE; BRONCHODILATOR AGENTS; ETHANOLAMINES; FEMALE; HEART; HEART FUNCTION TESTS; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; POWDERS; STEREOISOMERISM;

EID: 0033006646     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050607     Document Type: Article

References (31)

1. Bartow RA, Brogden RN (1998) Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 55: 302-322
2. Faulds D, Hollingshead LM, Goa KL (1991) Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42: 115-137
3. Häcki MA, Hinz GW, Medici TC (1997) Clinical experience over five years of daily therapy with formoterol in patients with bronchial asthma. Clin Drug Invest 14: 165-174
4. Derom EY, Pauwels RA (1992) Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 47: 30-33
5. Maesen FPV, Smeets SJ, Costongs MAL, Zweers PGMA, Pfeil JPJ (1995) Onset of action of eformoterol by dry powder inhaler: objective and subjective measures. Br J Clin Pract 49: 294-296
6. Lindén A, Rabe KF, Löfdahl CG (1996) Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting β2-adrenoceptor agonists. Lung 174: 1-22
7. Trofast J, Österberg K, Källström BL, Waldeck B (1991) Steric aspects of agonism and antagonism at β-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality 3: 443-450
8. Butter JJ, van den Berg BTJ, Portier EJG, Kaiser G, van Boxtel CJ (1996) Determination by HPLC with electrochemical detection of formoterol RR and SS enantiomers in urine. J Liq Chromatogr Rel Technol 19: 993-1005
9. van den Berg BTJ, Portier EJG, van den Berg M, Braat MCP, van Boxtel CJ (1994) First high-performance liquid chromatography assay of formoterol concentrations in the low-pico-gram-per-mililiter range. Ther Drug Monit 16: 196-199
10. Derks MGM, van den Berg BTJ, van der Zee JS, Braat MCP, van Boxtel CJ (1997) Biphasic effect-time courses in man after formoterol inhalation: eosinopenic and hypokalemic effects and inhibition of allergic skin reactions. J Pharmacol Exp Ther 283: 824-832
11. Braat MCP, Portier EJG, van den Berg BTJ, van den Berg M, van Boxtel CJ (1992) Formoterol detection and pharmacokinetics in human subjects after an oral dose of 168 micrograms. Am Rev Resp Dis 145 (4, part 2): A60
12. van den Berg BTJ, Koolen MGJ, Braat MCP, van Boxtel CJ (1994) Pharmacokinetic-pharmacodynamic interaction of formoterol and theophyllin. Am J Resp Crit Care Med 149: A470
13. Campestrini J, Lecaillon JB, Godbillon J (1997) Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection. J Chromatogr B Biomed Sci Appl 704: 221-229
14. Kaiser G, Bindschedler M, Butter JJ, van den Berg BTJ, van Boxtel CJ (1996) Urinary excretion of formoterol and its enantiomers after formoterol inhalation. Eur J Drug Metab Pharmacokinet, Special Issue (6th European Congress on Biophamaceuticals and Pharmacokinetics, Athens, Greece, 22-24 April, 1996): 140
15. Anonymous (1983) Metropolitan Life Height and Weight Table, Metropolitan Life insurance company
16. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
17. Sasaki H, Kamimura H, Shiobara Y, Esumi Y, Takaichi M, Yokoshima T (1982) Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. Xenobiotica 12: 802-812
18. Schütz H, Faigle JW, Winkler T, Kriemler HP (1988) The disposition of formoterol fumarate in man: comparison with in vitro biotransformation in animals. Poster 3.52 presented at the 11th Drug Metabolism Workshop, September 11-16, 1988, Konstanz, Germany
19. Bindschedler M, Kaiser G, Preiswerk G, Patalano F (1997) Biochemical and cardiovascular effects and urinary excretion of formoterol in healthy subjects after single inhaled doses. Am J Respir Crit Care Med 155 (4, part 2): A345
20. Anderson GP (1993) Formoterol: pharmacology, molecular basis of agonism and mechanisms of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 52: 2145-2160
21. Anderson GP, Linden A, Rabe KF (1994) Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7: 569-578
22. Strauss MH, Reeves RA, Smith DL, Leenen FH (1986) The role of cardiac β1-receptors in the hemodynamic response to a β2-agonist. Clin Pharmacol Ther 40: 108-115
23. Brown JE, McLeod AA, Shand DG (1983) Evidence for cardiac β2-adrenoceptors in man. Clin Pharmacol Ther 33: 424-428
24. Tattersfield AE, Britton JR (1988) β-Adrenoceptor agonists. In: Barnes PJ, Rodger IW, Thomson NC (eds) Asthma: basic mechanisms and clinical management. Academic Press, London, pp 563-606
25. Crane J, Burgess C, Beasley R (1989) Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol and isoprenaline. Thorax 44: 136-140
26. Maesen FPV, Costongs R, Smeets JJ, Brombacher PJ, Zweers PGMA (1991) The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentrations. Chest 99: 1367-1373
27. Brown MJ (1985) Hypokalemia from β2-receptor stimulation by circulating epinephrine. Am J Cardiol 56: 3D-9D
28. Vincent HH, Man in't Veld AJ, Boomsma F, Schalekamp MADH (1985) Prevention of epinephrine-induced hypokalemia by non selective beta blockers. Am J Cardiol 56: 10D-14D
29. Scheinin M, Koulu M, Laurikainen E, Allonen H (1987) Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers. Br J Clin Pharmacol 24: 645-653
30. Libretto SE (1994) A review of the toxicology of salbutamol (albuterol). Arch Toxicol 68: 213-216
31. Leitch AG, Clancy LJ, Costello JF, et al (1976) Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men. BMJ 1: 365-367